Indian drugmaker Syncom Formulations' Q2 revenue rises 16.8%

By Reuters News


Overview

  • Indian drugmaker's Q2 consolidated revenue from operations rose 16.8% to INR 1.42 bln

  • Consolidated profit for the period rose 60.6% to INR 266.5 mln

  • Diluted EPS rose to INR 0.28 from INR 0.18


Outlook

  • Company did not provide specific financial guidance for upcoming quarters or full year in its press release


Result Drivers

  • PHARMA REVENUE – Pharmaceuticals drugs and formulations segment revenue rose about 16.5% to INR 1.47 bln from INR 1.26 bln yr/yr in Q2

  • OPERATING EXPENSES – Consolidated operating expenses rose nearly 7% to INR 1.12 bln


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Consol Revenue from OPS

INR 1.42 bln

Q2 Consol Net Profit

INR 266.5 mln


Reuters Recommended Reads

  • Nov 12 - India's P&G Hygiene and Health profit drops as costs bite

  • Nov 13 - Gillette India's quarterly profit rises as cost savings cushion commodity pressures

  • Nov 12 - Germany's Dermapharm 9M revenue rises on growth in branded pharmaceuticals segment


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.